

We claim:

1. A pharmaceutical association characterized by being based in either tinidazole or secnidazole and  
5 flucozanol and/or an esteroisomer or an acceptable estereoisomeric mixture thereof, in a relationship of from 100 to less than 150 mg fluconazole and from 1000 to less than 2000 tinidazole or secnidazol, for the preparation of a medication for the treatment of infectious diseases in  
10 the female reproductive system.

2. A composition characterized by being based on a tinidazole and fluconazole and/or an estereoisomer or an estereoisomeric mixture of the same, in a relationship from 50 to less than 150 mg of fluconazole and 1000 mg to  
15 less than 2000 mg of tinidazole, for the preparation of a medication in the treatment of infectious diseases in the female reproductive system.

3. The composition according to claim 2, characterized by the relationship of the pharmaceutical  
20 association is of  $75\% \pm 20\%$  in weight of fluconazole and  $6\% \pm 20\%$  of tinidazole and the rest of pharmaceutically acceptable vehicles.

4. The composition according to claim 3, characterized in addition because it can be dosified in a  
25 pharmaceutical manner for oral administration.

5. The composition according to claim 3, characterized by the fact that the composition is administered in tablet form.

6. The composition according to claim 2,  
5 characterized in addition by the fact that the vehicle mixture of acceptable pharmaceutical vehicles comprises microcrystalline cellulose, sodium glycolate of starch, polyvinylpyrrolidone, magnesium stearate and white opadry.

7. A method for the treatment of infectious  
10 diseases in the female reproductive system, comprising in giving a patient suffering such a disease a mono dose in one day of the composition mentioned in Claim 2.

8. A method for the treatment of infectious diseases in accordance to claim 7, characterized because  
15 the mixed infections have been caused by *Gardnerella Vaginalis*, *Astinomyces*, *Candida*, *Micrococcus*, yeast, *Proteus*, *Micrococcus*, *E. Coli*, *Trichomonas Vaginilis* and *Trichomonas V.*, micro organisms present in vaginitis and vaginosis.

20 9. The method according to claim 8, characterized by the fact that the composition is provided in a one-tablet form.

10. The method according to claim 7 characterized by the fact that it is administered in a

mono dose and containing approximately 112.5 mg of fluconazole and approximately 1.5 g of tinidazole.

11. The use of an association of compounds which contains fluconazole and tinidazole, wherein the active  
5 ingredients are to be found in a relationship from 100 to less than 150 mg fluconazole and from 1000 to less than 2000 mg of tinidazole to prepare a medication useful in the treatment of infectious diseases in the female reproductive system.

10 12. The use according to claim 11, characterized by comprising 112.5 mg of fluconazole and 1.5 g of tinidazole.